Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Design Therapeutics, Inc.NASDAQ: DSGN
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$19.71M, compared with -$20.42M a year earlier. Trailing-twelve-month operating income was -$78.76M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -27.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.71M-8.5% QoQ
- Last fiscal yearDec 2025
- -$79.47M-27.4% YoY
- LTMMar 2026
- -$78.76M-15.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.5% | +100.0% | +96.5 pp |
| 1 year | -27.4% | +100.0% | +127.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (79.47M) USD
- Year-over-year change
- -27.4%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.47M) | -27.4% |
| FY2024 | 2024-12-31 | (62.38M) | +20.2% |
| FY2023 | 2023-12-31 | (78.19M) | -15.7% |
| FY2022 | 2022-12-31 | (67.59M) | -88.6% |
| FY2021 | 2021-12-31 | (35.83M) | — |
Operating Income vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 operating income of -$78.76M is the 3rd highest of the 11 companies compared; the peer median is -$178.84M.
- Its year-over-year change of -15.1% is the 3rd highest of 11, against a peer median of -60.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $116.26M | -83.8% | — | 11.5% | |
| LTM Mar 2026 | -$40.96M | +65.1% | — | 1.9% | |
| LTM Mar 2026 | -$78.76M | -15.1% | — | — | |
| LTM Mar 2026 | -$81.23M | +25.7% | — | — | |
| LTM Mar 2026 | -$86.55M | -594.3% | — | — | |
| LTM Mar 2026 | -$172.43M | -63.7% | — | — | |
| LTM Mar 2026 | -$185.25M | -584.4% | — | 577.5% | |
| LTM Mar 2026 | -$196.46M | -37.5% | — | — | |
| LTM Mar 2026 | -$196.88M | -56.6% | — | 274.2% | |
| LTM Jun 2026 | -$536.96M | -21.8% | — | — | |
| LTM Sep 2026 | -$565.42M | -103.4% | — | 58.9% | |
| Peer median (excluding DSGN) | -$178.84M | -60.1% | — | 58.9% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.